Hypoxia-Selective Antitumor Agents. 9. Structure-Activity Relationships for Hypoxia-Selective Cytotoxicity among Analogs of 5-[N,N-Bis(2-chloroethyl)amino]-2,4-dinitrobenzamide

Journal of Medicinal Chemistry

Volumn 37, Issue 14, 1994, Pages 2175-2184

  Palmer, Brian D ^a,b   Wilson, William R ^a,c   Atwell, Graham J ^a,b   Schultz, Diane ^a,c   Xu, Xing Z ^a,c   Denny, William A ^a,b  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Cancer Research Laboratory   (New Zealand)

^c Department of Pathology ^*  (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

5 (1 AZIRIDINYL) 2,4 DINITROBENZAMIDE; 5 [N,N BIS(2 CHLOROETHYL)AMINO] 2,4 DINITROBENZAMIDE; 5 [N,N BIS(2 CHLOROETHYL)AMINO] N [2 (DIMETHYLAMINO)ETHYL] 2,4 DINITROBENZAMIDE; BENZAMIDE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); SN 23862; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL GROWTH; CHO CELL; CONTROLLED STUDY; CYTOTOXICITY; DRUG SELECTIVITY; DRUG SYNTHESIS; GROWTH INHIBITION; HYPOXIA; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; WALKER CARCINOMA;

ANILINE MUSTARD; ANIMAL; ANTINEOPLASTIC AGENTS; CELL HYPOXIA; CHO CELLS; HAMSTERS; NAD(P)H DEHYDROGENASE (QUINONE); RATS; STRUCTURE-ACTIVITY RELATIONSHIP; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0028246907     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00040a009     Document Type: Article

References (40)

1. Bush, R. S.; Jenkin, R. D. T.; Allt, W. E. C.; Beale, F. A.; Bean, H.; Dembo, A. J.; Pringle, J. F. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br. J. Cancer 1978, 37, 302-306.
2. Gatenby, R. A.; Kessler, H. B.; Rosenblum, J. S.; Coia, L. R.; Moldofsky, P. J.; Hartz, W. H. Oxygen distribution in squamous cell carcinoma metastases and its relationship to outcome of radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1988, 14, 831-838.
3. Hockel, M.; Knoop, C.; Schlenger, K.; Vorndran, B.; Baubmann, E.; Mitze, M.; Knapstein, P. G.; Vaupel, P. Intratumoral pO2 predicts survival in advanced cancer of the uterine cervix. Radiother. Oncol. 1993, 26, 45-50.
4. Wilson, W. R. Tumour hypoxia: challenges for cancer chemotherapy. In Cancer Biology and Medicine; Waring, M. J., Ponder, B. A. J., Eds.; Kluwer Academic Publishers: Lancaster, 1992; Vol. 3, pp 87-131.
5. Rockwell, S.; Keyes, S. R.; Loomis, R.; Kelley, M.; Vyas, D. M.; Wong, H.; Doyle, T. W.; Sartorelli, A. C. Activity of C-7 substituted cyclic acetal derivatives of mitomycin C and porfiromycin against hypoxic and oxygenated EMT6 carcinoma cells in vitro and in vivo. Cancer Commun. 1991, 3, 191-198.
6. Hendriks, H. R.; Pizao, P. E.; Berger, D. P.; Kooistra, K. L.; Bibby, M. C.; Boven, E.; Dreefvandermeulen, H. C.; Henrar, R. E. C.; Fiebig, H. H.; Double, J. A.; Hornstra, H. W.; Pinedo, H. M.; Workman, P.; Schwartsmann, G. E09 - a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models. Eur. J. Cancer 1993, 29A, 897-906.
7. Sebolt-Leopold, J. S.; Elliot, W. L.; Showalter, H. D. H.; Leopold, W. R. Rationale for selection of PD 144872, the R-isomer of RB 6145, for clinical development as a radiosensitiser. Proc. Am. Assoc. Cancer Res. 1993, 34, 362.
8. Riley, R.; Hemingway, S. A.; Graham, M. A.; Workman, P. Initial characterization of the major mouse cytochrome-P450 enzymes involved in the reductive metabolism of the hypoxic cytotoxin 3-amino-1,2,4-benzotriazine-1,4-di-N-oxide (tirapazamine, SR-4233, WIN-59075). Biochem. Pharmacol. 1993, 45, 1065-1077.
9. Marshall, R. S.; Rauth, A. M. Oxygen and exposure kinetics as factors influencing the cytotoxicity of porfiromycin, a mitomycin C analogue, in Chinese hamster ovary cells. Cancer Res. 1988, 48, 5655-5659.
10. Koch, C. J. Unusual oxygen dependence of toxicity of SR-4233, a hypoxic cell toxin. Cancer Res. 1993, 53, 3992-3997.
11. Wilson, W. R.; Moselen, J. W.; Cliffe, S.; Denny, W. A.; Ware, D. C. Exploiting tumor hypoxia through bioreductive release of diffusible cytotoxins: the cobalt(III)-nitrogen mustard complex SN 24771. Int. J. Radiat. Oncol. Biol. Phys., in press.
12. Whillans, D. W.; Hunt, J. W. A rapid mixing comparison of the mechanisms of radiosensitization by oxygen and misonidazole. Radiat. Res. 1982, 90, 126-141.
13. Denny, W. A.; Wilson, W. R. Bioreducible mustards: a paradigm for hypoxia-selective prodrugs of diffusible cytotoxins (HPDCs). Cancer Met. Rev. 1993, 12, 135-151.
14. Palmer, B. D.; Wilson, W. R.; Pullen, S. M.; Denny, W. A. Hypoxia-selective antitumor agents. 3. Relationships between structure and cytotoxicity against cultured tumour cells for substituted N,N-bis(2-chloroethyl) anilines. J. Med. Chem. 1990, 33, 112-121.
15. Denny, W. A.; Wilson, W. R. Considerations for the design of nitrophenyl mustards as agents with selective toxicity for hypoxic mammalian cells. J. Med. Chem. 1986, 29, 879-887.
16. Panthananickal, A.; Hansch, C.; Leo, A. Structure-activity relationships in antitumor aniline mustards. J. Med. Chem. 1978, 21, 16-26.
17. Palmer, B. D.; Wilson, W. R.; Cliffe, S.; Denny, W. A. Hypoxia-selective antitumor agents. 5. Synthesis of water-soluble nitroaniline mustards with selective cytotoxicity for hypoxic mammalian cells. J. Med. Chem. 1992, 35, 3214-3222.
18. Wilson, W. R.; Palmer, B. D.; Pullen, S. M.; Cliffe, S.; Denny, W. A. SN 23862, an analogue of CB 1954 with decreased DT-diaphorase sensitivity and improved hypoxia-selective cytotoxicity. 40th Ann. Meeting Radiation Research Soc. 1992, p 59, Abstract.
19. Knox, R. J.; Boland, M. P.; Friedlos, F.; Coles, B.; Southan, C.; Roberts, J. J. The nitroreductase enzyme in Walker cells that activates 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) to 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide is a form of NAD-(P)H dehydrogenase (quinone) (EC 1.6.99.2). Biochem. Pharmacol. 1988, 37, 4671-4677.
20. Knox, R. J.; Friedlos, F.; Jarman, M.; Roberts, J. J. A new cytotoxic, DNA interstrand crosslinking agent agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2,4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in Walker carcinoma cells. Biochem. Pharmacol. 1988, 37, 4661-4667.
21. Goldstein, H.; Stamm, R. 4,6-Dinitro-3-chlorobenzoic acid. Helv. Chim. Acta 1952, 35, 1330-1332
22. Davis, F. A.; Stringer, O. D. Chemistry of oxaziridines. 2. Improved synthesis of 2-sulfonyloxaziridines. J. Org. Chem. 1982, 47, 1774-1775.
23. Herbert, R. B.; Hollman, R. G. Phenazines. VI. The synthesis of some 2-aminophenazines and 2-aminocarboxyphenazinesulphonamides. Tetrahedron 1965, 21, 663-675.
24. Springer, C. J.; Antoniw, P.; Bagshawe, K. D.; Wilman, D. E. V. Comparison of half-lives and cytotoxicity of N-chloroethyl-4-amino and N-mesyloxyethylbenzoyl compounds, products of prodrugs in antibody-directed enzyme prodrug therapy (ADEPT). Anti-Cancer Drug Des. 1991, 6, 467-479.
25. Wilson, W. R.; Anderson, R. F.; Denny, W. A. Hypoxia-selective antitumor agents. 1. Relationship between structure, redox properties and hypoxia-selective cytotoxicity for 4-substituted derivative of nitracrine. J. Med. Chem. 1989, 32, 23-30.
26. Thompson, L. H.; Busch, H.; Brookman, K.; Mooney, C. L.; Glaser, D. A. Genetic diversity of UV-sensitive DNA repair mutants of Chinese hamster ovary cells. Proc. Natl. Acad. Sci. U.S.A. 1980, 78, 3734-3741.
27. Hoy, C. A.; Thompson, L. H.; Mooney, C. L.; Salazar, E. P. Defective DNA crosslink removal in Chinese hamster cell mutants sensitive to bifunctional alkylating agents. Cancer Res. 1985, 45, 1737-1747.
28. Kohn, K. W.; Ewigra, G.; Erickson, L. C.; Zwelling, L. A. Measurement of strand breaks and crosslinks by alkaline elution. In DNA Repair. A Laboratory Manual of Research Procedures; Friedberg, E., Hanawalt, P., Eds.; Marcel Dekker: New York, 1981; pp 379-401.
29. Roberts, J. J.; Friedlos, F.; Knox, R. J. CB 1954 (2,4-dinitro-5-aziridinyl benzamide) becomes as DNA interstrand crosslinker in Walker tumour cells. Biochem. Biophys. Res. Commun. 1986, 140, 1073-1078.
30. Whillans, D. W.; Rauth, A. M. An experimental and analytical study of oxygen depletion in stirred cell suspensions. Radiat. Res. 1980, 34, 97-103.
31. Hansch, C.; Leo, A. Substituent Constants for Correlation Analysis in Chemistry and Biology; Wiley-Interscience: New York, 1979.
32. Boland, M.P.; Knox, R. J.; Roberts, J. J. The differences in kinetics of rat and human DT diaphorase result in a differential sensitivity of derived cell lines to CB 1954 (5-(aziridin-1-yl)-2,4-dinitrobenzamide). Biochem. Pharmacol. 1991, 41, 867-875.
33. Lind, C.; Cadenas, E.; Hochstein, P.; Ernster, L. DT-diaphorase: purification, properties and function. Methods Enzymol. 1990, 186, 287-301.
34. Horie, S. Advances in research on DT-diaphorase - catalytic properties, regulation of activity and significance in the detoxification of foreign compounds. Kitasato Arch. Exp. Med. 1990, 63, 11-30.
35. Plumb, J. A.; Thomson, P.; Workman, P. Marked sensitization to EO9 under hypoxic conditions in a cell line deficient in DT-diaphorase activity. 8th International Conference on Chemical Modifiers of Cancer Treatment, 1993, p 63, Abstract.
36. Siim, B. G.; Atwell, G. J.; Wilson, W. R. Metabolic and radiolytic reduction of 4-alkylammo-5-nitroquinoline bioreductive drugs: relationship to selectivity for hypoxic cells. Biochem. Pharmacol., in press.
37. Finlay, G. J.; Baguley, B. C.; Wilson, W. R. A semiautomated microculture method for investigating growth inhibitory effects of cytotoxic compounds on exponentially growing carcinoma cells. Anal. Biochem. 1984, 139, 272-277.
38. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983, 65, 55-63.
39. Hill, R. P.; Gulyas, S.; Whitmore, G. F. Studies of the in vivo and in vitro cytotoxicity of the drug RSU-1069. Br. J. Cancer 1986, 53, 743-751.
40. Cobb, I. M.; Connors, T. A.; Elson, L. A.; Khan, A. H.; Micheley, B. C. V.; Ross, W. C. J.; Whisson, M. E. 2,4-Dinitro-5-ethylene-iminobenzamide (CB 1954); a potent and selective inhibitor of the growth of the Walker carcinoma 256. Biochem. Pharmacol. 1969, 18, 1519-1527.